The sector remains the most painful of all sectors. We got a little rally yesterday only to be crushed this morning. This sort of trading is very frustrating especially because the sector is so oversold that there should be some dead cat bounce rally coming at the very least. One can see the move today […]
December 2nd Biotech Update
The sector is good at one thing and that is creating despair and frustration. The selloff has just been relentless and this is very much sentiment related. You can have relentless selling when fundamentals change, i.e. the energy sector at the start of the pandemic when the economy was shut down. There is nothing happening […]
December 1st Biotech Update
It is hard to be optimistic with the sector. We are well overdue for a bounce and if we assume that we are in a bear market these rallies can be significant. I have been looking at the sector as being in a large range and now that has been clearly broken. Is there a […]
November 29th Biotech Update
I think we are likely going to look back at Friday and see it as an Omicron overreaction given that it is still unclear if this mutation is more dangerous than delta or can outcompete delta as the dominant strain. In addition, all the oral treatments that are on the way will still work against […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
